A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
12
Infusion of 150 µg/h during 48h
Infusion of 100 µg/h during 48h
Infusion of 50 µg/h during 48h
Pulmonary Capillary Wedge Pressure
Time frame: 8 hours
Cardiac index (CI)
Time frame: 8 hours and 48 hours
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: Follow up (30 + 5 days)
Right atrial pressure (RAP)
Time frame: 8 hours and 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Infusion of placebo during 48h
Unnamed facility
Ridgewood, New Jersey, United States
Unnamed facility
Winston-Salem, North Carolina, United States
Unnamed facility
Cleveland, Ohio, United States
Unnamed facility
Fairfield, Ohio, United States
Unnamed facility
Philadelphia, Pennsylvania, United States
Unnamed facility
Philadelphia, Pennsylvania, United States
Unnamed facility
Vienna, State of Vienna, Austria
Unnamed facility
Linz, Upper Austria, Austria
Unnamed facility
Zagreb, Croatia
Unnamed facility
Helsinki, Finland
...and 49 more locations